Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BAY 2586116 in Healthy Japanese Males
NCT04872387Phase 1Completed
- Sponsor
- Bayer
- Start
- May 2021
- Primary completion
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BAY2586116 in obstructive sleep apnea (OSA) (3 arms), sponsored by Bayer. Primary endpoint: Number of participants with adverse events. Started May 2021; status: completed.
02
Drugs
BAY2586116
03
Conditions
obstructive sleep apnea (OSA)
Beyond the preview
Go deeper on NCT04872387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04872387.